Skip to main content

Rheumatology

The Rheumatology Research Group (GRR) is focused on translational research in immunity-mediated inflammatory diseases (IMIDA), mainly in the area of rheumatology. The GRR is a multidisciplinary group made up of clinical specialists, biologists, bioinformaticians and laboratory technicians. The different research lines of the GRR emphasize the use of high-performance technologies for the study at the cellular and molecular level of the immununopathology of IMIDA, mainly chronic inflammatory arthritis and autoimmune systemic diseases.

At the clinical level, we have developed lines of research in very diverse areas of rheumatology, including chronic inflammatory arthritis (rheumatoid arthritis, spondyloarthropathies), systemic autoimmune diseases (lupus, myositis, Sjögren's syndrome), the study of musculoskeletal imaging, pediatric rheumatology (juvenile idiopathic arthritis, autoimmune systemic diseases, autoinflammatory syndromes), central sensitization syndromes and the study of bone metabolism. One of the main objectives of the GRR is the coordination of basic and clinical research to accelerate the transfer of knowledge to clinical practice and thus improve the quality of life of patients.

Team

Luis Coronel Tarancon

Luis Coronel Tarancon

Senior researcher
Rheumatology
Read more
Marta Muste Diaz

Marta Muste Diaz

Rheumatology
Read more
Mayte Serrat Lopez

Mayte Serrat Lopez

Postdoctoral researcher
Rheumatology
Read more
Miriam Almirall Bernabé

Miriam Almirall Bernabé

Rheumatology
Read more
Montse Sender Beleta

Montse Sender Beleta

Research technician
Rheumatology
Read more
Nuria Palau Balaña

Nuria Palau Balaña

Postdoctoral researcher
Rheumatology
Read more
Luis Coronel Tarancon

Luis Coronel Tarancon

Senior researcher
Rheumatology
Read more
Marta Muste Diaz

Marta Muste Diaz

Rheumatology
Read more
Mayte Serrat Lopez

Mayte Serrat Lopez

Postdoctoral researcher
Rheumatology
Read more
Miriam Almirall Bernabé

Miriam Almirall Bernabé

Rheumatology
Read more
Montse Sender Beleta

Montse Sender Beleta

Research technician
Rheumatology
Read more
Nuria Palau Balaña

Nuria Palau Balaña

Postdoctoral researcher
Rheumatology
Read more

Projects

Disfunción autonómica y ritmo circadiano en el Síndrome de Fatiga Crónica/Encefalomielitis Miálgica: nuevas herramientas diagnósticas y terapéuticas en la enfermedad

IP: José Alegre Martin
Collaborators: Jesus Castro Marrero, Jesus Castro Marrero, Jesus Castro Marrero, Jesus Castro Marrero, Jesus Castro Marrero, Jesus Castro Marrero, Jesus Castro Marrero, Jesus Castro Marrero
Funding agency: Instituto de Salud Carlos III
Funding: 87120
Reference: PI19/00629
Duration: 01/01/2020 - 30/06/2024

Inmunomonitorización personalizada para estratificar los pacientes con lupus eritematoso sistémico

IP: Josefina Cortes Hernandez
Collaborators: Teresa Moline Marimon, Sheila Bermejo Garcia
Funding agency: Instituto de Salud Carlos III
Funding: 141570
Reference: PI21/00287
Duration: 01/01/2022 - 31/12/2024

Estratificación de pacientes con artritis reumatoide en la terapia anti-TNF. Caracterización espacial del transcriptoma de la membrana sinovial asociada a la respuesta a tratamiento y asociación a biomarcadores proteómicos.

IP: Antonio Julia Cano
Collaborators: Juan Jose De Agustin De Oro, Nuria Palau Balaña, Adria Aterido Ballonga
Funding agency: Instituto de Salud Carlos III
Funding: 196020
Reference: PI21/01185
Duration: 01/01/2022 - 30/06/2026

Novel therapeutic topical approach for discoid lupus cutaneous (DLE) treatment

IP: Cristina Solé Marce
Collaborators: Berta Ferrer Fábrega, Gloria Aparicio Español
Funding agency: Instituto de Salud Carlos III
Funding: 99099
Reference: PI21/01869
Duration: 01/01/2022 - 31/12/2025

Blog

News

The session focused on the scientific, regulatory and clinical challenges of advanced therapy medicinal products, from preclinical research to first-in-human trials.

Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research

Transaction expands Formation Bio's immunology pipeline with Phase 1 ready drug candidate.